Mads D.M. Engelmann

1 ta ish

Novo Nordisk (Denmark)

1. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

   Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres +9

   MaqolaOAOchiq kirish20212 iqtibos

   ABIABI:AkademIndex/2026.other.216651